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ABSTRACT
	 To explore the role of Chemokine (C-C motif) ligand 8 (CCL8) as a potential biomarker for acute graft-versus-
host disease (aGVHD), we retrospectively analyzed the sera and clinical course of 31 patients with grade II–IV 
aGVHD. No deaths occurred in the ten patients with serum CCL8 concentrations less than 213 pg/mL, whereas 11 of 
the 21 patients with more than 213 pg/mL died within 180 days post-transplantation. This landmark analysis 
revealed a significantly lower survival rate of patients with a CCL8 serum concentration greater than 213 pg/mL. 
Thus, elevated serum CCL8 concentration before day 100 post-transplantation may predict aGVHD prognosis.
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1. Introduction
 Allogeneic hematopoietic stem cell transplantation 
(HSCT) is widely used as a treatment for hematological 
and malignant diseases. However, despite the 
development of potent immunosuppressive agents, 
acute graft-versus-host disease (aGVHD) continues to 
be a major contributor to non-relapse mortality (NRM), 
such as infection, veno-occlusive disease and 
thrombotic microangiopathy (TAM), of patients treated 
with allogeneic HSCT for malignant diseases. 1, 2）
 Employing proteomic techniques, we have shown 
that CC chemokine-ligand motif 8 (CCL8) is a potential 
biomarker for the diagnosis of aGVHD. 3, 4）We now 
report that elevated serum CCL8 concentration after 
HSCT closely correlates with NRM in humans. Thus, 
serum CCL8 levels might be a potential prognostic 
biomarker for the clinical outcome of grade II–IV 
aGVHD.
2. Patients and Methods
 Thirty-one patients with grade II to IV aGVHD 
who underwent HSCT between May 1993 and 
February 2005 in the Department of Pediatrics at 
Sapporo Medical University Hospital or Department of 
Hematology and Oncology at the Children's Medical 
Center of Japanese Red Cross Nagoya First Hospital 
were retrospectively analyzed. Grading of GVHD was 
based on the report from the 1994 Consensus 
Conference. 5）
 Blood samples were obtained from patients 
undergoing allogeneic HSCT in the two hospitals 
after obtaining informed consent from the patients 
or their parents. The Ethics Committee of both 
hospitals approved the human sera studies. Sera 
had been collected  on at least two occasions, 
aliquoted, and stored at －80ºC until use in assays. 
Human CCL8 enzyme-linked immunosorbent assay 
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(ELISA) kits were obtained from Immuno-Biological 
Laboratories (Gunma, Japan) and used according to 
the manufacturer's protocol. 6）
 We retrospectively analyzed patient deaths 
that occurred within 180 days after HSCT. To 
examine any possible correlation between serum 
CCL8 level and the NRM of these patients, we 
chose the largest value of serum CCL8 acquired in 
the early phase of aGVHD as a representative 
CCL8 concentration for an individual case. Thus, 
serum CCL8 hereafter corresponds to the largest 
value of serum CCL8 amongst each patient's 
samples.
 Statistical analysis was performed using JMP® 
9 (SAS Institute, Cary, NC). The cut-off value of 
serum CCL8 correlating with NRM was determined 
b y  g e n e r a t i o n  o f  a  R e c e i v e r  O p e r a t i n g 
Characteristic (ROC) curve. The Kaplan-Meier 
method was used to estimate survival rate, while 
log-rank and generalized Wilcoxon tests were used 
to assess differences in survival among patients 
groups. A landmark analysis method was used to 
assess the impact of CCL8 levels on survival by 
correcting for inherent bias in the analysis of time-
to-event outcome between groups. 7）For landmark 
analysis, we set the landmark time to day 100 after 
HSCT because aGVHD is defined to develop within 
100 days after HSCT. Values for significant 
difference were set at p < 0.05.
3. Results
 Patient characteristics are shown in Table I. 
The median age was 8 years (range 1–21 years). 
Eleven patients died of infection, hemorrhage, TAM 
or other complications within 180 days after HSCT. 
The remaining 20 patients included six patients 
who died after day 180 with causes of death 
including pneumonia (n = 1) ,  TAM (n = 1) , 
secondary brain tumor (n = 1), and recurrence of 
initial disease (n = 3). Only one patient (UPN24) 
suffered a relapse within 180 days after HSCT. The 
performance of CCL8 for prediction of NRM was 
assessed by quantifying the area under the ROC 
curve (area under the curve is 0.741, Figure 1A). 
The cutoff value for serum CCL8 concentration was 
213 pg/mL, corresponding to a specificity of 50% 
and sensitivity of 100%, and the likelihood ratio of 
a positive test was 2.0. According to serum CCL8 
level, patients were divided into two groups: Group 
1 (n = 21) included patients with a serum CCL8 
concentration > 213 pg/mL, while Group 2 (n = 10) 
included patients with a serum CCL8 concentration 
< 213 pg/mL. Median day of aGVHD onset was 15 
days after HSCT in Group 1 and 20 days in Group 2 
(p = 0.08). Median serum CCL8 concentration was 
512.9 pg/mL in Group 1 and 111.3 pg/mL in Group 
2, and average CCL8 was 561.6 pg/mL in Group 1 
and 119.8 pg/mL in Group 2 (p < 0.01).
 Figure 1B depicts days of post-HSCT (x-axis) 
and highest value of serum CCL8 concentration 
(y-axis) up to 180 days post-HSCT. The vertical 
solid line indicates day 100 post-HSCT. The 
horizontal dotted line corresponds to 213 pg/mL of 
CCL8. All cases (100%) exhibited the highest serum 
CCL8 value before day 100 post-HSCT during the 
observation period. Open circles correspond to 
individuals who were still alive at day 180, while 
closed circles indicate individuals who died within 
180 days post-HSCT. The deaths of the eleven 
individuals who died within 180 days post-HSCT 
were all non-relapse associated.
 Figure 1C shows the survival rate at 180 days 
post-HSCT in all the patients with grade II–IV 
aGVHD (n = 31). Group 1 (solid line, serum CCL8 > 
213 pg/mL) showed a significantly lower survival 
rate at 180 days after HSCT compared with Group 
2 (dashed line, serum CCL8 < 213 pg/mL) (P < 0.01, 
log-rank and Wilcoxon tests). This result suggests 
that serum CCL8 concentration can predict NRM 
before day 180.
 Figure 1D shows the results of landmark 
analysis. The landmark point was set at day 100 
a fter  HSCT because aGVHD is  def ined as 
developing within 100 days after HSCT.
4. Discussion 
 We previously reported that serum CCL8 
concentration closely correlates with the survival of 
GVHD model mice, suggesting that chemotactic 
activity of this C-C chemokine may play a role in 
tissue injury associated with GVHD. 4）Our findings 
here indicate that the largest serum CCL8 value 
obtained during the early phase of grade II–IV 
aGVHD could predict NRM within 180 days after 
HSCT. Indeed, serum CCL8 values were relatively 
high in the early phase of aGVHD and slowly 
decreased with immunosuppressive treatment (data 
not shown). These results suggest that the 
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Table I. Patients’ Characteristics
Patient
No
age at
SCT Sex
Underlying
Disease HSCT Source
GVHD
prophylaxis
aGVHD onset 
day a
aGVHD
grade
MAX
CCL8 b
Non-relapse
deaths
MAX CCL8
day a
day a of
death
UPN01 6 F AML（M2） MSD-BMT MTX 32 3 213.74 yes 84 107
UPN02 2 F AML（M4） UR-CBT FK+shortMTX 11 3 825.68 yes 12 118
UPN03 4 F FHL UR-BMT CsA+shortMTX 9 3 271.03 yes 76 82
UPN04 5 M ALL UR-BMT CsA+shortMTX 22 3 515.5 yes 14 49
UPN05 5 F ALL UR-BMT CsA+shortMTX 22 3 299.07 yes 12 55
UPN06 7 M CML UR-BMT FK+shortMTX 12 3 339.41 yes 20 38
UPN07 10 F ALL UR-BMT CsA+shortMTX 12 4 512.9 yes 12 58
UPN08 11 F ALL UR-BMT CsA+shortMTX 10 4 840.1 yes 10 114
UPN09 12 F ALL mis-UR-BMT
CsA+
shortMTX 10 4 818.56 yes 65 132
UPN10 14 M T-lymphoma UR-BMT
FK+
shortMTX 10 3 593.7 yes 11 64
UPN11 21 M AA>MDS UR-BMT CsA+shortMTX 13 3 750.2 yes 15 145
UPN12 1 M infantile ALL mis-UR-BMT
FK+
shortMTX 97 3 73.94 no 14
UPN13 3 M AA UR-BMT CsA+shortMTX 22 2 442.37 no 12
UPN14 5 M Ph-ALL MSD-BMT MTX 19 3 174.51 no 18 562
UPN15 5 M Fanconi Anemia UR-CBT CsA+MMF 10 3 115.3 no 10 251
UPN16 6 F AA UR-BMT CsA+shortMTX 26 3 682.41 no 15
UPN17 7 M ALL UR-BMT FK+shortMTX 12 2 1118.53 no 17
UPN18 7 M ALL MSD-BMT MTX 27 2 205.6 no 61 2962
UPN19 7 M ALL UR-CBT FK+shortMTX 5 3 736.82 no 12
UPN20 8 M AA UR-BMT CsA+shortMTX 17 3 240.85 no 16
UPN21 8 M AML（M2） MSD-BMT MTX 26 3 160.79 no 20
UPN22 8 M AA mis-BMT（CD34+）
CsA+
shortMTX 73 3 107.3 no 97
UPN23 10 F Ph-ALL MSD-BMT MTX 18 2 441.8 no 14 468
UPN24 10 M AA>MDS（RAEB-t） UR-BMT
CsA+
shortMTX 37 3 846.28 no 47 317
UPN25 10 M AML（M2） UR-BMT FK+shortMTX 21 3 457.52 no 13
UPN26 10 M CML UR-BMT FK+shortMTX 19 3 85.1 no 19
UPN27 11 F AA UR-BMT CsA+shortMTX 16 2 421.36 no 20
UPN28 11 M ALL UR-BMT
CsA+
shortMTX+
mPSL
28 2 20.4 no 28
UPN29 13 M Ph-ALL UR-BMT FK+shortMTX 25 2 100.99 no 20
UPN30 17 F ALL MSD-BMT CsA+shortMTX 20 2 154.04 no 13
UPN31 20 F AA UR-BMT CsA+shortMTX 111 3 425.67 no 48 1239
a) the day of HSCT is day0.  The blanks mean that the patient lives, b) MAX CCL8 corresponds to the maximum level of serum CCL8 after the HSCT.
Abbreviations in the Table I
aGVHD: acute　graft-versus-host　disease
HSCT:　hematopoietic　stem　cell　transplantation
BMT:　bone　marrow　transplantation
UR-BMT:　unrelated　BMT
MSD-BMT:　matched　sibling　donor　BMT
UR-CBT:　unrelated　cord　blood　stem　cell　transplantation
ALL:　acute　lymphoblastic　leukemia
AML:　acute　myeloblastic　leukemia
AA:　aplastic　amemia
MDS: myelodysplastic syndrome
CML: chronic myelocytic leukemia
FHL: familial hemophagocytic lymphohistiocytosis
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Figure 1. 
A) Receiver operator characteristic (ROC) curve of Chemokine (C-C motif) ligand 8 (CCL8) versus non-relapse deaths areas. 
Area under the curve is 0.741. The cutoff value of serum CCL8 concentration is 213 pg/mL, corresponding to a specificity of 
50% and sensitivity of 100%, and the likelihood ratio of a positive test is 2.0.
B) Distribution of maximum serum CCL8 concentration of each patient during the course of post-transplantation up to 180 
days. Vertical solid line indicates day 100 post-transplantation. Horizontal dotted line indicates serum concentration of 213 
pg/ml of CCL8. One circle corresponds to one patient. Open circles correspond to individuals alive at day 180, whereas 
closed circles indicate individuals who died within 180 days. All cases (100%) exhibited a maximum level of CCL8 before 
day 100 post-transplantation.
C) Evaluation of survival by Kaplan-Meier curve and log rank test. Patients with a maximum serum CCL8 concentration over 
213 pg/mL (Group 1, solid line, CCL8 > 213 pg/ml, n = 21) showed a significantly lower survival rate at day 180 post-
transplantation compared with individuals whose levels were lower than 213 pg /mL (Group 2, dashed line, CCL8 < 213 
pg/ml, n = 10). Values of significance were similar in log rank (p = 0.0076) and Wilcoxon (p = 0.0087) tests.
D) Evaluation of the survival of 31 patients with grade II-IV aGVHD and recorded maximum serum CCL8 levels before day 
100 post-transplantation by the landmark method at day 100. Patients with a maximum serum CCL8 concentration over 
213 pg/mL (Group 1, solid line, CCL8 > 213 pg/ml, n = 21) showed a significantly lower survival rate at day 180 post-
transplantation compared with individuals whose levels were less than 213 pg /mL (Group 2, dashed line, CCL8 < 213 
pg/ml, n = 10). Values of significance were similar in log rank (p = 0.0076) and Wilcoxon (p = 0.0087) tests.
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chemotactic activity and/or other functions of CCL8 
could contribute quantitatively to aGVHD 
pathology, and are associated with prognosis. 
However, the precise mechanism by which CCL8 
contributes to aGVHD has not been determined.
 Glucksberg grading has been used to assess the 
clinical severity of aGVHD, with its maximum grade 
correlating with aGVHD prognosis. 8）However, the 
grade at onset is not helpful for prognostication. 
While several biomarkers for aGVHD have been 
proposed. 9-12）, the absolute value of any single 
biomarker has not been found useful for evaluating 
aGVHD prognosis. Levine et al.  reported a 
biomarker panel consisting of six biomarkers for 
predicting the treatment outcome and prognosis of 
aGVHD patients. 13）However, using a formula to 
assess the values of several biomarkers risks over-
fitting. Nonetheless, there need to be more accurate 
studies regarding biomarkers and their potential 
usefulness for GVHD in clinical settings. In our 
results, the absolute value of CCL8 could predict the 
prognosis of aGVHD.
 Although elevated serum CCL8 concentration 
within 100 days post-HSCT may predict NRM in 
patients with grade II–IV aGVHD, there are a few 
drawbacks of this cohort study. First, the sample 
size is too small to draw a definitive conclusion. 
Second, there might be a sampling bias, as this 
study was retrospective and the sampling times 
(days post-transplantation) varied. However, 
although there are some controversial points, our 
results are encouraging to launch a prospective 
observational study.
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非血縁者間同種造血細胞移植後早期の血清中 CCL8 発現は
移植後非再発死亡率と相関する
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　急性移植片対宿主病（GVHD）におけるバイオマー
カーとしてケモカイン CCL8 の役割を明らかにする
ため，grade II-IV の急性 GVHD 患者 31 名の血清
と臨床経過を後方視的に解析した．血清 CCL8 濃度が，
213pg/mL 以上であった 21 名中 11 名が移植後 180 日
以内に死亡していたが，血清 CCL8 濃度が 213pg/mL
以下であった 10 名には死亡が見られなかった．ラン
ドマーク解析でも CCL8 濃度が 213pg/mL 以上では
明らかに生存率が低かった．移植後 100 日前の血清
CCL8 濃度上昇は急性 GVHD の予後を予見しうるこ
とが示唆された．
